Office of Technology Transfer
About Harvard UniversitySee more information at Harvard Biological Laboratories.
579 articles with Harvard University
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Study Published in Nature Biomedical Engineering Demonstrates the Unique Capabilities of Torus Biosystems Donut PCR System
Torus Biosystems, Inc., a point of care molecular diagnostics company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, announced the publication of performance results for its Donut PCR system.
Here’s a look at some of the top COVID-19-related stories for today.
The Wyss Institute for Biologically Inspired Engineering at Harvard University announces that it is collaborating with multiple industry partners to discover more effective approaches to deliver drugs across the blood-brain barrier for the treatment of brain diseases.
The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.
Obatala Sciences licenses technology from Harvard University to advance discovery in obesity, diabetes, and cancer
Obatala Sciences, a biotechnology company that manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, has been granted an exclusive license from Harvard University to commercialize innovations that enable the study of human fat tissue in vitro.
Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer
Harvard University has granted an exclusive license to biotechnology company Obatala Sciences to commercialize innovations that enable the study of human fat tissue in vitro.
Repertoire believes the findings, which provide an updated understanding of viral antigen presentation and epitope selection, may assist in vaccine development for COVID-19.
Harvard University licenses its nasal swab collection technology, developed at the Wyss Institute and Harvard Medical School, to Mass. startup Rhinostics
The combined technologies could reduce labor and time required for COVID-19 diagnostic testing 10-fold, and facilitate future diagnostic testing of other respiratory diseases.
Harvard University and Kyowa Kirin Co., Ltd. announce that they have entered into a strategic research alliance.
Harvard's Wyss Institute collaborates with GBS Inc. on the Wyss' eRapid-based COVID-19 diagnostic to help curb the pandemic
Combination of the Wyss' electrochemical sensing technology with GBS's transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in point-of-care applications.
NORTHPOND VENTURES: Harvard's Wyss Institute Creates Research And Innovation Alliance With Northpond Labs
Northpond commits $12 million to create a Laboratory for Bioengineering Research and Innovation at the Wyss Institute for solutions-oriented research and development
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
In a groundbreaking new study, scientists at Harvard University have identified one enzyme that seems to dictate the limits of our physical performance.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
Color and Researchers from Massachusetts General Hospital and the Broad Institute Discover Key Finding to Determine Risk of Genomic Diseases
The research, published August 20 in Nature Communications, unveils the relationship between monogenic variants and polygenic risk for coronary artery disease, breast cancer, and colorectal cancer.
Medical device company will pursue development of strong, biocompatible adhesive that could replace sutures and dental membranes
Charles Lieber, the former chair of Harvard University’s Chemical Biology Department, was indicted by a federal grand jury this week on two counts of making false statements.
These “backpacks” keep key immune cells in a tumor-killing state for up to five days after they approach a tumor.
Collaboration supports advancement of Harvard biomedical research and Astellas drug discovery research in a range of therapeutic areas